WEDNESDAY, June 25, 2025 (HealthDay News) — For patients with recessive dystrophic epidermolysis bullosa (RDEB), a one-time surgical application of prademagene zamikeracel, an autologous COL7A1 gene-modified cellular sheet that is sutured onto a large, chronic RDEB wound, improves wound healing and pain versus standard of care, according to a study published online June 23 in […]
The post Gene Therapy Effective in Patients With Recessive Dystrophic Epidermolysis Bullosa first appeared on Physician’s Weekly.
